Published On Oct 29, 2024, 5:03 PM
Eli Lilly (LLY) is expected to exceed Wall Street's Q3 earnings forecasts. Analysts are optimistic due to strong sales from its key drugs, particularly in the diabetes and obesity segments. This positive sentiment has been reflected in the stock's recent performance and overall growth in the pharmaceutical sector.
Positive
Based on the anticipated strong earnings results and positive sales trajectory of key products, Eli Lilly appears to be in a strong position to continue its upward momentum. Investors may want to consider buying ahead of the earnings report, especially if they believe the upcoming earnings will lead to further growth in share price.
Sep 17, 2024, 5:32 PM
GLP-1 pills are the next frontier for the weight-loss market.
Investor's Business Daily executive editor Alissa Coram discusses whether the 'down' stock market is due for a bounce this week on 'Varney & Co.'
Sep 6, 2024, 4:52 PM
The telehealth world is entering a new phase of vertical integration in healthcare.